Apellis Pharmaceuticals Growth, Revenue, Number of Employees and Funding

Overview

Location:
Crestwood, KY USA
Total Funding:$163.3M
Industry:Biotech
Founded:2008
Lead Investor(s):Sectoral Asset Management
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Apellis Pharmaceuticals's estimated revenue is currently $7.4M per year.
  • Apellis Pharmaceuticals received $60.0M in venture funding in August 2017.
  • Apellis Pharmaceuticals's estimated revenue per employee is $36293
  • Apellis Pharmaceuticals's total funding is $163.3M.

Employee Data

  • Apellis Pharmaceuticals has 205 Employees.
  • Apellis Pharmaceuticals grew their employee count by 138% last year.
  • Apellis Pharmaceuticals currently has 38 job openings.

Executive Contacts

NameTitle
Cedric FrancoisCo-founder & CEO/President
Pascal DeschateletsChief Operating Officer
David WatsonGeneral Counsel and Vice President of Corporate Development
Federico GrossiChief Medical Officer
Derek WachtelAssociate Director, DMPK
Kristopher WeatherbyAssociate Director, Technical Operations
Mark DeLongVP, Business Development & Strategy
Frank StoutDirector Clinical Operations
Adam TownsendChief Commercial Officer
Stacey HollonHR Director

What Is Apellis Pharmaceuticals?

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases.

keywords:Biotechnology,Healthcare,Pharmaceuticals

205

Number of Employees

$7.4M

Revenue (est)

38

Current Jobs

138%

Employee Growth %

$163.3M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Sherwin
$7.6M5230%
Apellis Pharmac...
$7.4M205138%$163.3M

Apellis Pharmaceuticals News

09/03/2019 - Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass. and CRESTWOOD, Ky., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (APLS) a clinical-stage ...

09/08/2019 - Apellis Pharmaceuticals to Present at Upcoming Investor ...

CRESTWOOD, Ky. and WALTHAM Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage ...

09/03/2019 - Alps Advisors Inc. Has $3.35 Million Stock Position in Apellis Pharmaceuticals Inc (NASDAQ:APLS)

Alps Advisors Inc. cut its holdings in Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 2.6% during the 2nd quarter, according to the company in ...

Apellis Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2014-12-03$33.0MUndisclosedMorningside VenturesArticle
2016-01-11$32.0MUndisclosedArticle
2016-02-15$47.0MDCormorant Asset ManagementArticle
2017-08-11$60.0MESectoral Asset ManagementArticle

Apellis Pharmaceuticals Executive Hires

DateNameTitleReference
2016-08-09Robert KimChief Medical OfficerArticle
2017-12-20Timothy SullivanCFOArticle
2018-11-21Adam TownsendChief Commercial OfficerArticle
2019-02-01Thomas LacknerSVP/Head of EuropeArticle

Apellis Pharmaceuticals Acquisitions

DateCompany NameAmountNotesReference
2014-11-21Potentia Pharmaceuticals, IncArticle